GTHX [NASD]
G1 Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.61 Insider Own0.90% Shs Outstand50.60M Perf Week11.23%
Market Cap368.08M Forward P/E- EPS next Y-2.96 Insider Trans-28.86% Shs Float46.49M Perf Month43.16%
Income-153.90M PEG- EPS next Q-0.83 Inst Own51.30% Short Float / Ratio6.64% / 2.57 Perf Quarter-32.70%
Sales46.80M P/S7.87 EPS this Y-35.00% Inst Trans13.05% Short Interest3.09M Perf Half Y-10.80%
Book/sh1.07 P/B6.94 EPS next Y14.90% ROA-74.60% Target Price29.57 Perf Year-18.97%
Cash/sh2.48 P/C2.99 EPS next 5Y- ROE-173.00% 52W Range3.84 - 17.49 Perf YTD36.83%
Dividend- P/FCF- EPS past 5Y-22.80% ROI-65.50% 52W High-57.52% Beta1.64
Dividend %- Quick Ratio3.90 Sales past 5Y- Gross Margin93.30% 52W Low93.49% ATR0.46
Employees148 Current Ratio4.20 Sales Q/Q381.60% Oper. Margin- RSI (14)66.21 Volatility5.94% 7.15%
OptionableYes Debt/Eq1.67 EPS Q/Q41.10% Profit Margin- Rel Volume1.45 Prev Close6.71
ShortableYes LT Debt/Eq1.67 EarningsNov 02 BMO Payout- Avg Volume1.20M Price7.43
Recom2.00 SMA2023.25% SMA5020.19% SMA200-10.27% Volume1,743,585 Change10.73%
Jan-30-23Upgrade JP Morgan Underweight → Neutral $7 → $10
Jan-03-23Reiterated Needham Buy $32 → $31
Nov-04-21Downgrade JP Morgan Neutral → Underweight $20 → $19
Oct-15-21Resumed BTIG Research Buy $51
Sep-30-21Downgrade JP Morgan Overweight → Neutral $24 → $20
Nov-17-20Downgrade Raymond James Strong Buy → Outperform
Jun-26-20Initiated ROTH Capital Buy $55
Jan-21-20Reiterated H.C. Wainwright Buy $72 → $82
Aug-08-19Upgrade JP Morgan Neutral → Overweight
Feb-07-19Initiated B. Riley FBR Buy $55
Show Previous Ratings
Jan-11-23 07:00AM
Jan-09-23 06:30AM
Jan-04-23 11:01AM
06:30AM
Jan-03-23 02:00PM
06:04PM Loading…
Dec-07-22 06:04PM
Dec-01-22 11:41PM
Nov-27-22 10:09PM
Nov-23-22 10:30AM
Nov-22-22 04:01PM
Nov-17-22 08:12PM
04:01PM
Nov-03-22 08:17AM
Nov-02-22 10:19AM
07:45AM
06:30AM Loading…
06:30AM
06:28AM
Nov-01-22 05:40PM
Oct-28-22 09:40AM
Oct-26-22 09:26AM
Oct-21-22 06:42AM
Oct-19-22 12:30PM
Oct-12-22 09:40AM
Oct-10-22 06:30AM
Oct-03-22 05:00PM
Sep-10-22 08:03AM
Sep-07-22 08:00AM
Sep-06-22 07:00AM
Sep-01-22 05:22PM
Aug-26-22 09:55AM
09:55AM Loading…
Aug-08-22 09:55AM
Aug-04-22 04:30AM
Aug-03-22 07:45AM
06:30AM
Aug-01-22 05:15PM
09:00AM
Jul-31-22 08:03AM
Jul-28-22 10:03AM
Jul-27-22 10:02AM
Jul-25-22 06:30AM
Jul-20-22 09:00AM
Jul-13-22 10:15AM
Jul-09-22 09:54AM
Jul-01-22 05:20PM
04:45PM
Jun-28-22 07:30AM
Jun-13-22 07:00AM
Jun-02-22 11:00AM
Jun-01-22 04:45PM
May-24-22 08:04AM
May-20-22 10:30AM
May-18-22 10:15AM
May-07-22 10:11AM
May-04-22 07:45AM
06:30AM
May-02-22 05:30PM
Apr-27-22 03:03PM
Apr-21-22 08:30AM
Apr-06-22 11:30AM
Apr-01-22 04:15PM
Mar-31-22 04:05PM
Mar-30-22 06:46AM
Mar-07-22 10:58AM
Mar-01-22 05:00PM
11:15AM
Feb-23-22 01:30PM
07:45AM
06:30AM
Feb-09-22 09:15AM
Feb-01-22 05:30PM
Jan-05-22 05:06AM
Jan-04-22 09:15AM
Jan-03-22 05:30PM
Dec-16-21 06:00AM
Dec-01-21 06:20PM
07:00AM
Nov-29-21 07:00AM
Nov-12-21 08:25AM
Nov-10-21 11:40AM
Nov-06-21 10:45AM
Nov-03-21 04:01PM
07:45AM
06:30AM
Nov-01-21 06:00PM
Oct-27-21 03:03PM
Oct-20-21 08:00AM
Oct-07-21 08:00AM
Oct-01-21 04:30PM
07:45AM
Sep-22-21 07:35AM
Sep-15-21 06:45AM
Sep-03-21 07:45AM
07:30AM
Aug-08-21 03:27AM
Aug-05-21 10:00AM
03:31AM
Aug-04-21 05:15PM
04:01PM
08:00AM
Aug-02-21 06:50AM
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MURDOCK TERRY LChief Operating OfficerJan 05Sale5.417293,94236,439Jan 05 08:26 PM
Moses Jennifer K.CFOJan 05Sale5.417293,94257,820Jan 05 08:26 PM
Hanson James S.General CounselJan 05Sale5.417293,94241,087Jan 05 08:25 PM
Malik RajeshChief Medical OfficerJan 05Sale5.417293,942102,739Jan 05 08:25 PM
MURDOCK TERRY LChief Operating OfficerJan 04Sale5.581,6399,13837,168Jan 05 08:26 PM
Moses Jennifer K.CFOJan 04Sale5.581,6399,13858,549Jan 05 08:26 PM
Hanson James S.General CounselJan 04Sale5.581,6399,13841,816Jan 05 08:25 PM
Malik RajeshChief Medical OfficerJan 04Sale5.581,6399,138103,468Jan 05 08:25 PM
Perry AndrewChief Commercial OfficerJan 04Sale5.588204,57221,300Jan 05 08:25 PM
Bailey John E. (Jack) Jr.President and CEOJan 04Sale5.585,60731,262276,282Jan 05 08:23 PM
Bailey John E. (Jack) Jr.President and CEOJan 03Sale5.8532,019187,452281,889Jan 05 08:23 PM
Malik RajeshChief Medical OfficerDec 15Option Exercise0.3014,0004,20087,207Dec 16 04:12 PM
Velleca Mark A.DirectorOct 18Option Exercise0.3915,0005,850131,000Oct 20 04:05 PM
Velleca Mark A.DirectorOct 18Sale11.7015,000175,490116,000Oct 20 04:05 PM
Velleca Mark A.DirectorSep 20Option Exercise0.3920,0007,800136,000Sep 22 04:40 PM
Velleca Mark A.DirectorSep 20Sale13.5020,000270,044116,000Sep 22 04:40 PM
Malik RajeshChief Medical OfficerSep 13Option Exercise0.3918,0007,02091,207Sep 16 04:31 PM
Malik RajeshChief Medical OfficerSep 13Sale15.7118,000282,74673,207Sep 16 04:31 PM
Velleca Mark A.DirectorAug 16Option Exercise0.3980,00031,200196,000Aug 18 04:06 PM
Velleca Mark A.DirectorAug 16Sale12.6480,0001,010,904116,000Aug 18 04:06 PM
Malik RajeshChief Medical OfficerJul 05Sale5.176483,35173,207Jul 06 04:02 PM
MURDOCK TERRY LChief Operating OfficerJul 05Sale5.176483,35120,907Jul 06 04:03 PM
Velleca Mark A.DirectorFeb 07Option Exercise0.3915,0005,850116,000Feb 08 04:05 PM
Moses Jennifer K.CFOFeb 01Option Exercise4.112,3339,57937,888Feb 02 05:20 PM
Malik RajeshChief Medical OfficerFeb 01Option Exercise0.3010,0003,00073,855Feb 02 05:20 PM